K H Park1, S Lee2, J H Park3, S Y Kang4, H Y Kim5, I H Park6, Y H Park7, Y H Im7, H J Lee8, S Park9, S I Lee10, K H Jung11, Y S Kim12, Jae Hong Seo13. 1. Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, 73 Inchonro, Sungbuk-Gu, Seoul, 02481, South Korea. 2. Division of Oncology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 3. Division of Oncology/Hematology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan, South Korea. 4. Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, South Korea. 5. Division of Oncology/Hematology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Pyeongchon, Anyang-si, Gyeonggi-do, South Korea. 6. Center for Breast Cancer and Center for Clinical Trials, National Cancer Center, Goyang-si, South Korea. 7. Division of Hematology/Oncology, Department of Internal Medicine, Samsung Medical Center, Seoul, South Korea. 8. Product Development HQ, Dong-A ST, Seoul, South Korea. 9. Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic University College of Medicine, Seoul, South Korea. 10. Division of Oncology/Hematology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea. 11. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 12. Division of Oncology/Hematology, Department of Internal Medicine, Kosin University Gospel Hospital, Busan, South Korea. 13. Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, 73 Inchonro, Sungbuk-Gu, Seoul, 02481, South Korea. cancer@korea.ac.kr.
Abstract
PURPOSE: This multi-center, randomized, phase III study was conducted to demonstrate the non-inferiority of DA-3031 compared with daily filgrastim in patients during the first cycle of chemotherapy for breast cancer in terms of the duration of severe neutropenia (DSN). METHODS:Seventy-four patients with breast cancer who were receivingcombination chemotherapy with docetaxel, doxorubicin, and cyclophosphamide (TAC) were enrolled. All participants were randomized to receive either daily subcutaneous injections of filgrastim 100 μg/m2/day for up to 10 days or a single subcutaneous injection of DA-3031 at fixed doses of 6 mg on day 2 of each chemotherapy cycle. RESULTS: The mean duration of grade 4 (G4) neutropenia in cycle 1 was 2.08 ± 0.85 days for the filgrastim group and 2.28 ± 1.14 days for the DA-3031 group. The difference between groups was 0.2 ± 1.10 days (95 % confidence interval (CI) = -0.26, 0.66), which supported non-inferiority. No statistically significant differences were observed in nadir absolute neutrophil count (ANC) (154.34/mm3 and 161.75/mm3 for the filgrastim and DA-3031 groups, respectively; P = 0.8414) or in time to ANC recovery (10.03 ± 0.75 and 9.83 ± 1.56 days in the filgrastim and DA-3031 groups, respectively; P = 0.0611) during cycle 1. Serious AEs occurred in six (15.8 %) patients receiving filgrastim and in ten (27.8 %) patients receiving DA-3031; however, none was determined to be related to the study drug. CONCLUSIONS:DA-3031 and daily filgrastim are similar in regard to DSN and safety in breast cancer patients receiving TAC chemotherapy.
RCT Entities:
PURPOSE: This multi-center, randomized, phase III study was conducted to demonstrate the non-inferiority of DA-3031 compared with daily filgrastim in patients during the first cycle of chemotherapy for breast cancer in terms of the duration of severe neutropenia (DSN). METHODS: Seventy-four patients with breast cancer who were receiving combination chemotherapy with docetaxel, doxorubicin, and cyclophosphamide (TAC) were enrolled. All participants were randomized to receive either daily subcutaneous injections of filgrastim 100 μg/m2/day for up to 10 days or a single subcutaneous injection of DA-3031 at fixed doses of 6 mg on day 2 of each chemotherapy cycle. RESULTS: The mean duration of grade 4 (G4) neutropenia in cycle 1 was 2.08 ± 0.85 days for the filgrastim group and 2.28 ± 1.14 days for the DA-3031 group. The difference between groups was 0.2 ± 1.10 days (95 % confidence interval (CI) = -0.26, 0.66), which supported non-inferiority. No statistically significant differences were observed in nadir absolute neutrophil count (ANC) (154.34/mm3 and 161.75/mm3 for the filgrastim and DA-3031 groups, respectively; P = 0.8414) or in time to ANC recovery (10.03 ± 0.75 and 9.83 ± 1.56 days in the filgrastim and DA-3031 groups, respectively; P = 0.0611) during cycle 1. Serious AEs occurred in six (15.8 %) patients receiving filgrastim and in ten (27.8 %) patients receiving DA-3031; however, none was determined to be related to the study drug. CONCLUSIONS:DA-3031 and daily filgrastim are similar in regard to DSN and safety in breast cancerpatients receiving TAC chemotherapy.
Entities:
Keywords:
Breast cancer; Neutropenia; Pegylated G-CSF; TAC chemotherapy
Authors: D R Budman; D A Berry; C T Cirrincione; I C Henderson; W C Wood; R B Weiss; C R Ferree; H B Muss; M R Green; L Norton; E Frei Journal: J Natl Cancer Inst Date: 1998-08-19 Impact factor: 13.506
Authors: Miguel Martin; Tadeusz Pienkowski; John Mackey; Marek Pawlicki; Jean-Paul Guastalla; Charles Weaver; Eva Tomiak; Taher Al-Tweigeri; Linnea Chap; Eva Juhos; Raymond Guevin; Anthony Howell; Tommy Fornander; John Hainsworth; Robert Coleman; Jeferson Vinholes; Manuel Modiano; Tamas Pinter; Shou C Tang; Bruce Colwell; Catherine Prady; Louise Provencher; David Walde; Alvaro Rodriguez-Lescure; Judith Hugh; Camille Loret; Matthieu Rupin; Sandra Blitz; Philip Jacobs; Michael Murawsky; Alessandro Riva; Charles Vogel Journal: N Engl J Med Date: 2005-06-02 Impact factor: 91.245
Authors: M Martín; A Lluch; M A Seguí; A Ruiz; M Ramos; E Adrover; A Rodríguez-Lescure; R Grosse; L Calvo; C Fernandez-Chacón; M Roset; A Antón; D Isla; P Martínez del Prado; L Iglesias; J Zaluski; A Arcusa; J M López-Vega; M Muñoz; J R Mel Journal: Ann Oncol Date: 2006-06-09 Impact factor: 32.976
Authors: Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-02-13 Impact factor: 44.544
Authors: W C Wood; D R Budman; A H Korzun; M R Cooper; J Younger; R D Hart; A Moore; J A Ellerton; L Norton; C R Ferree Journal: N Engl J Med Date: 1994-05-05 Impact factor: 91.245
Authors: Matti Aapro; Matthias Schwenkglenks; Gary H Lyman; Antonio Lopez Pousa; Susan Lawrinson; Tomas Skacel; Pamela Bacon; Gunter von Minckwitz Journal: Crit Rev Oncol Hematol Date: 2009-09-11 Impact factor: 6.312
Authors: Ki Hyeong Lee; Ji-Yeon Kim; Moon Hee Lee; Hye Sook Han; Joo Han Lim; Keon Uk Park; In Hae Park; Eun Kyung Cho; So Young Yoon; Jee Hyun Kim; In Sil Choi; Jae Hoo Park; Young Jin Choi; Hee-Jun Kim; Kyung Hae Jung; Si-Young Kim; Do-Youn Oh; Seock-Ah Im Journal: Support Care Cancer Date: 2015-10-01 Impact factor: 3.603